Vestor Capital LLC Sells 39,345 Shares of Becton, Dickinson and Company (NYSE:BDX)

Vestor Capital LLC decreased its holdings in Becton, Dickinson and Company (NYSE:BDXFree Report) by 69.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,716 shares of the medical instruments supplier’s stock after selling 39,345 shares during the period. Vestor Capital LLC’s holdings in Becton, Dickinson and Company were worth $4,320,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Becton, Dickinson and Company by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after purchasing an additional 516,427 shares during the last quarter. Morgan Stanley increased its stake in Becton, Dickinson and Company by 4.5% during the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock worth $2,637,062,000 after buying an additional 435,168 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Becton, Dickinson and Company by 11.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock valued at $1,342,503,000 after acquiring an additional 512,566 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Becton, Dickinson and Company by 9.2% during the third quarter. Ameriprise Financial Inc. now owns 3,630,351 shares of the medical instruments supplier’s stock valued at $938,593,000 after acquiring an additional 304,629 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its stake in shares of Becton, Dickinson and Company by 2.9% in the third quarter. Clearbridge Investments LLC now owns 3,135,238 shares of the medical instruments supplier’s stock worth $810,553,000 after acquiring an additional 89,714 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.3 %

NYSE BDX traded up $0.77 during trading on Friday, hitting $235.77. The stock had a trading volume of 2,034,395 shares, compared to its average volume of 1,424,967. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $68.14 billion, a PE ratio of 51.59, a PEG ratio of 1.92 and a beta of 0.45. The firm has a 50 day moving average price of $238.14 and a 200 day moving average price of $239.89. Becton, Dickinson and Company has a twelve month low of $229.40 and a twelve month high of $287.32.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter in the previous year, the business posted $2.86 earnings per share. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Insider Activity at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares in the company, valued at $1,252,750.61. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

Separately, Barclays lifted their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $281.40.

Check Out Our Latest Stock Report on Becton, Dickinson and Company

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Further Reading

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.